AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 279: H1000-H1006, 2000;
0363-6135/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lainchbury, J. G.
Right arrow Articles by Redfield, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lainchbury, J. G.
Right arrow Articles by Redfield, M. M.
Vol. 279, Issue 3, H1000-H1006, September 2000

Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs

John G. Lainchbury, Donna M. Meyer, Michihisa Jougasaki, John C. Burnett Jr., and Margaret M. Redfield

Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Physiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905

Myocardial actions of the vasodilator peptide adrenomedullin (ADM) in the intact animal are unknown. Negative and positive inotropic actions have been reported in ex vivo experiments. Myocardial and load-altering actions of ADM in dogs before and after development of heart failure were studied. With controlled heart rate (atrial pacing) and after beta -blockade, ADM was administered to five normal dogs in doses of 20 ng · kg-1 · min-1 iv, 100 ng · kg-1 · min-1 iv, and 200 ng · kg-1 · min-1 into the left ventricle (LV). LV peak systolic pressure and end-systolic volume decreased with each dose of ADM. End-systolic pressure decreased with the two higher doses. At the highest dose, arterial elastance and the time constant of LV isovolumic relaxation (tau ) decreased, and LV end-systolic elastance (Ees) increased. LV end-diastolic pressure and volume were unchanged. In five additional normal dogs receiving only the highest dose of ADM (200 ng · kg-1 · min-1 intra-LV), to control for increased heart rate and sympathetic activation observed with the cumulative infusion, ADM produced arterial vasodilation but no change in Ees or tau . In four dogs with pacing-induced heart failure, ADM (200 ng · kg-1 · min-1 intra-LV) was without effect on tau , Ees, and systolic or diastolic pressure and volume. In vivo, ADM appears to be a selective arterial dilator without inotropic or lusitropic effects. The vasodilatory actions are attenuated in heart failure.

inotrope; hemodynamics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Bisping, G. Tenderich, P. Barckhausen, B. Stumme, S. Bruns, D. von Lewinski, and B. Pieske
Atrial myocardium is the predominant inotropic target of adrenomedullin in the human heart
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3001 - H3007.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. V. Maniu, D. M. Meyer, and M. M. Redfield
Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension
Hypertension, October 1, 2002; 40(4): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Y. T. Hart, J. C. Burnett Jr., and M. M. Redfield
Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1938 - H1945.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Y.T. Hart, D. M. Meyer, H. D. Tazelaar, J. P. Grande, J. C. Burnett Jr, P. R. Housmans, and M. M. Redfield
Load Versus Humoral Activation in the Genesis of Early Hypertensive Heart Disease
Circulation, July 10, 2001; 104(2): 215 - 220.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online